Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri ^® ) Dosing: NOVA Phase IIIb Extension Study (Part 2).

Autor: Wiendl H; Department of Neurology with Institute of Translational Neurology, University of Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany. heinz.wiendl@ukmuenster.de., Foley J; Rocky Mountain MS Clinic, Salt Lake City, UT, USA., Defer G; Centre Hospitalier Universitaire de Caen, Caen, France., Zhovtis Ryerson L; Hackensack Meridian Health Jersey Shore University Medical Center, Neptune City, NJ, USA., Cohen JA; Cleveland Clinic, Cleveland, OH, USA., Arnold DL; Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada., Butzkueven H; Central Clinic School, Monash University, Melbourne, Australia., Cutter GR; University of Alabama, Birmingham, AL, USA., Giovannoni G; Blizard Institute, London, UK., Killestein J; MS Centre Amsterdam, Amsterdam, The Netherlands., Domingo-Horne R; Biogen, Cambridge, MA, USA., Toukam M; Biogen, Cambridge, MA, USA., Nunn A; Cytel, London, UK., Maghzi AH; Biogen, Cambridge, MA, USA., Kuhelj R; Biogen, Baar, Switzerland., Lasky T; Biogen, Cambridge, MA, USA.

Publikováno v: Neurology and therapy [Neurol Ther] 2024 Oct; Vol. 13 (5), pp. 1385-1401. Date of Electronic Publication: 2024 Jul 24.